Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million
Mandate

Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million

February 20, 2023 Capital Markets and Public M&A

Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Adrian Filipovic.

Related

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

 Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026

Vinge advises Accru Partners on its EUR 550 million senior secured bond issuance

 Vinge advises Accru Partners, backed by Axcel, in connection with Accru Partners’ inaugural EUR 550 million issuance of senior secured bonds.
September 23, 2026

Vinge advises Sveafastigheter on EUR 350 million bond issuance

 Vinge has advised Sveafastigheter AB (publ) on the issuance of EUR 350 million in senior unsecured bonds under its existing EUR 2 billion EMTN programme.
September 23, 2026